Cited by 332SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesAnimal Virus Infections Studies

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

Open access

Weissman, Drew, Alameh, Mohamad-Gabriel, de Silva, Thushan, Collini, Paul, Hornsby, Hailey, Brown, Rebecca, LaBranche, Celia C., Edwards, Robert J., Sutherland, Laura, Santra, Sampa, Mansouri, Katayoun, Gobeil, Sophie, McDanal, Charlene, Pardi, Norbert, Hengartner, Nick, Lin, Paulo J.C., Tam, Ying, Shaw, Pamela A., Lewis, Mark G., Boesler, Carsten, Şahin, Uğur, Acharya, Priyamvada, Haynes, Barton F., Korber, Bette, Montefiori, David C.·2021·Cell Host & Microbe

DOI 10.1016/j.chom.2020.11.012PMC PMC7707640

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein acquired a D614G mutation early in the pandemic that confers greater infectivity and is now the globally dominant form. To determine whether D614G might also mediate neutralization escape that could compromise vaccine efficacy, sera from spike-immunized mice, nonhuman primates, and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 spike. In all cases, the G614 pseudovirus was moderately more susceptible to neutralization. The G614 pseudovirus also was more susceptible to neutralization by receptor-binding domain (RBD) monoclonal antibodies and convalescent sera from people infected with either form of the virus. Negative stain electron microscopy revealed a higher percentage of the 1-RBD "up" conformation in the G614 spike, suggesting increased epitope exposure as a mechanism of enhanced vulnerability to neutralization. Based on these findings, the D614G mutation is not expected to be an obstacle for current vaccine development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.chom.2020.11.012

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citation
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Self-citation
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 4×
“This is the immunogen being employed in the Moderna vaccine in phase 3 clinical trials (mRNA1273, NCT04470427) (Jackson et al., 2020).”
Influential
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Self-citation
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885

Show all 57 references

Sorted by citations

Items 101–200 of 332

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
Zou, J., Xie, X., Fontes-Garfias, C. R., Swanson, K. A., Kanevsky, I., Tompkins, K. R., Cutler, M. W., Cooper, D., Dormitzer, P. R., & Shi, P. (2021) · npj Vaccines · doi:10.1038/s41541-021-00313-8 · Cited by 42
D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage
Cheng, Y. W., Chao, T., Li, C., Wang, S.-H., Kao, H., Tsai, Y., Wang, H., Hsieh, C.-L., Lin, Y.-Y., Chen, P., et al. (2021) · mBio · doi:10.1128/mbio.00587-21 · Cited by 41
Evolution of the SARS-CoV-2 genome and emergence of variants of concern
Safari, I., & Elahi, E. (2021) · Archives of Virology · doi:10.1007/s00705-021-05295-5 · Cited by 41
Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera
Rathnasinghe, R., Jangra, S., Ye, C., Čupić, A., Singh, G., Martínez‐Romero, C., Mulder, L. C. F., Kehrer, T., Yildiz, S., Choi, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30763-0 · Cited by 42
SARS-CoV-2 variants: biology, pathogenicity, immunity and control
Uraki, R., Korber, B., Diamond, M., & Kawaoka, Y. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01255-x · Cited by 50
Self-citation
Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile
Beltrán-Pavez, C., Riquelme-Barrios, S., Oyarzún-Arrau, A., Gaete-Argel, A., González‐Stegmaier, R., Cereceda, K., Aguirre, A., Travisany, D., Palma-Véjares, R., Barriga, G. P., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe6855 · Cited by 37
SARS-CoV-2 Virus−Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response
Queirós-Reis, L., da Silva, P. G., Gonçalves, J., Brancale, A., Bassetto, M., & Mesquita, J. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910836 · Cited by 40
Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity
Zhou, W., Xu, C., Wang, P., Anashkina, A. A., & Jiang, Q. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab375 · Cited by 42
Identification of Potential Binding Sites of Sialic Acids on the RBD Domain of SARS-CoV-2 Spike Protein
Li, B., Wang, L., Ge, H., Zhang, X., Ren, P., Guo, Y., Chen, W., Li, J., Zhu, W. J., Chen, W., et al. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.659764 · Cited by 35
Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity
Alefishat, E. A., Jelinek, H. F., Mousa, M., Tay, G. K., & AlSafar, H. S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.01.007 · Cited by 39
Antigenic evolution of SARS coronavirus 2
Mykytyn, A. Z., Fouchier, R. A. M., & Haagmans, B. L. (2023) · Current Opinion in Virology · doi:10.1016/j.coviro.2023.101349 · Cited by 36
Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in Nicotiana benthamiana Plant as a Vaccine Candidate against COVID-19
Mamedov, T., Yuksel, D., Ilgın, M., Gürbüzaslan, İ., Gulec, B., MAMMADOVA, G., Özdarendeli, A., Yetişkin, H., Kaplan, B., Pavel, S. T. I., et al. (2021) · Vaccines · doi:10.3390/vaccines9111337 · Cited by 38
SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity
Neerukonda, S. N., Vassell, R. A., Lusvarghi, S., Wang, R., Echegaray, F., Bentley, L., Eakin, A. E., Erlandson, K. J., Katzelnick, L. C., Weiss, C. D., et al. (2021) · Viruses · doi:10.3390/v13122485 · Cited by 31
Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
Vidal, S. J., Collier, A.-R. Y., Yu, J., McMahan, K., Tostanoski, L. H., Ventura, J. D., Aïd, M., Peter, L. E., Jacob-Dolan, C., Anioke, T., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00404-21 · Cited by 34
Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2
Rodrigues, K. A., Rodriguez‐Aponte, S. A., Dalvie, N. C., Lee, J. H., Abraham, W. D., Carnathan, D. G., Jimenez, L. E., Ngo, J. T., Chang, J. Y. H., Zhang, Z., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj6538 · Cited by 36
Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice
Mamedov, T., Yuksel, D., Ilgın, M., Gürbüzaslan, İ., Gulec, B., Yetişkin, H., Uygut, M. A., Pavel, S. T. I., Özdarendeli, A., MAMMADOVA, G., et al. (2021) · Viruses · doi:10.3390/v13081595 · Cited by 34
Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations
Cocherie, T., Zafilaza, K., Leducq, V., Marot, S., Cálvez, V., Marcelin, A., & Todesco, È. (2022) · Microorganisms · doi:10.3390/microorganisms11010030 · Cited by 33
Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study
Prather, A. A., Dutcher, E. G., Robinson, J. E., Lin, J., Blackburn, E. H., Hecht, F. M., Mason, A. E., Fromer, E., Merino, B., Frazier, R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33320-x · Cited by 30
Antigenic variation of SARS‐CoV‐2 in response to immune pressure
Forni, D., Cagliani, R., Pontremoli, C., Mozzi, A., Pozzoli, U., Clerici, M., & Sironi, M. (2020) · Molecular Ecology · doi:10.1111/mec.15730 · Cited by 30
Photonics enabled intelligence system to identify SARS-CoV 2 mutations
Taha, B. A., Al-Jubouri, Q., Mashhadany, Y. I. M. A., Zan, M. S. D., Bakar, A. A. A., Fadhel, M. M., & Arsad, N. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-11930-1 · Cited by 32
Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic
Li, X., Zhang, L., Chen, S. E., Ji, W., Li, C., & Ren, L. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104971 · Cited by 30
Synergistic surface-enhanced Raman scattering effect to distinguish live SARS-CoV-2 S pseudovirus
Sitjar, J., Xu, H.-Z., Liu, C.-Y., Wang, J., Liao, J., Tsai, H., Lee, H., Liu, B. H., & Chang, C.-W. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.339406 · Cited by 30
Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccinationPreprint
Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.05.429759 · Cited by 29
Self-citation
Proteases and variants: context matters for SARS-CoV-2 entry assays
Stevens, C. S., Oguntuyo, K. Y., & Lee, B. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.07.004 · Cited by 28
Effectiveness and Efficacy of Vaccine on Mutated SARS-CoV-2 Virus and Post Vaccination Surveillance: A Narrative Review
Hafiz, I., Illian, D. N., Meila, O., Utomo, A. R. H., Susilowati, A., Susetya, I. E., Desrita, D., Siregar, G. A., & Basyuni, M. (2022) · Vaccines · doi:10.3390/vaccines10010082 · Cited by 31
Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques
Li, R., Ma, X., Deng, J., Chen, Q., Liu, W., Peng, Z., Qiao, Y., Lin, Y., He, X., & Zhang, H. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00641-8 · Cited by 29
Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
Lee, E.-J., & Oh, J. E. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0075 · Cited by 30
Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation
Chen, H.-Y., Huang, C., Tian, L., Huang, X., Zhang, C., Llewellyn, G. N., Rogers, G. L., Andresen, K., O’Gorman, M. R. G., Chen, Y., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00966-21 · Cited by 31
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization
Karger, A. B., Brien, J. D., Christen, J. M., Dhakal, S., Kemp, T. J., Klein, S. L., Pinto, L. A., Premkumar, L., Roback, J. D., Binder, R. A., et al. (2022) · mSphere · doi:10.1128/msphere.00193-22 · Cited by 28
Rapid and Sensitive Detection of SARS-CoV-2 Using Clustered Regularly Interspaced Short Palindromic Repeats
Tsou, J.-H., Liu, H., Stass, S. A., & Jiang, F. (2021) · Biomedicines · doi:10.3390/biomedicines9030239 · Cited by 27
Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19
Kaku, Y., Kuwata, T., Zahid, H. M., Hashiguchi, T., Noda, T., Kuramoto, N., Biswas, S., Matsumoto, K., Shimizu, M., Kawanami, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109385 · Cited by 26
Profiling of SARS-CoV-2 Subgenomic RNAs in Clinical Specimens
Chen, Z., Ng, R. W. Y., Lui, G. C.-Y., Ling, L., Chow, C., Yeung, A. C. M., Boon, S. S., Wang, M. H., Chan, K. C. C., Chan, R. W. Y., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00182-22 · Cited by 28
How SARS-CoV-2 first adapted in humans
Choe, H., & Farzan, M. (2021) · Science · doi:10.1126/science.abi4711 · Cited by 27
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27
Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galao, R. P., Lista, M. J., et al. (2021) · doi:10.1101/2021.02.03.429355 · Cited by 27
Genetic drift in the genome of SARS COV‐2 and its global health concern
Bano, I., Sharif, M., & Alam, S. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27337 · Cited by 23
Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics
Choi, H. M., Moon, S. Y., Yang, H.-I., & Kim, K. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041737 · Cited by 28
mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
Jin, Y., Hou, C., Li, Y., Zheng, K., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.821538 · Cited by 24
The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2
Fang, L., Xu, J., Zhao, Y., Fan, J., Shen, J., Liu, W., & Cao, G. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1228128 · Cited by 26
Inferring the Association between the Risk of COVID-19 Case Fatality and N501Y Substitution in SARS-CoV-2
Zhao, S., Lou, J., Chong, K. C., Cao, L., Zheng, H., Chen, Z., Chan, R. W. Y., Zee, B. C.-Y., Chan, P. K. S., & Wang, M. H. (2021) · Viruses · doi:10.3390/v13040638 · Cited by 23
Variants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody/vaccine sensitivity
Prüβ, B. M. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2702065 · Cited by 26
Structure-guided antibody cocktail for prevention and treatment of COVID-19
Su, S.-C., Yang, T., Yu, P., Liang, K.-H., Wy, C., Yang, C.-W., Lin, H.-T., Wang, M.-J. S., Lu, R., Tso, H.-C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009704 · Cited by 24
Dominant clade‐featured SARS‐CoV‐2 co‐occurring mutations reveal plausible epistasis: An in silico based hypothetical model
Alam, A. S. M. R. U., Islam, O. K., Hasan, M. S., Islam, M. R., Mahmud, S., Al‐Emran, H. M., Jahid, I. K., Crandall, K. A., & Hossain, M. A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27416 · Cited by 24
Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge
Winkler, M. S., Skirecki, T., Brunkhorst, F. M., Cajander, S., Cavaillon, J., Ferrer, R., Flohé, S. B., García‐Salido, A., Giamarellos‐Bourboulis, E. J., Girardis, M., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103291 · Cited by 26
SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications
Yuan, L., Tang, Q., Zhu, H., Guan, Y., Cheng, T., & Xia, N. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1976598 · Cited by 20
An overview of the ongoing challenges in SARS-CoV-2 global control
Shehata, A. A., Parvin, R., Nagy, A., Wang, Y., Azhar, T. M., Attia, Y. A., Azhar, E. I., Paul, A. K., & Rahmatullah, M. (2021) · German Journal of Microbiology · doi:10.51585/gjm.2021.2.0006 · Cited by 24
Uncovering the Genetic Links of SARS-CoV-2 Infections on Heart Failure Co-Morbidity by a Systems Biology Approach
Zhang, G., Cui, X., Zhang, L., Liu, G., Zhu, X., Shangguan, J., Zhang, W., Zheng, Y., Zhang, H., Tang, J., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14003 · Cited by 24
An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants
Huang, L., Zhao, F., He, M., Fang, Y., Ma, X., Lu, S., Li, E., Xiao, H. Q., Zhu, H., Wang, X., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.002 · Cited by 23
SARS-CoV-2 Spike Protein Extrapolation for COVID Diagnosis and Vaccine Development
Malik, Y. S., Kumar, P., Ansari, M. I., Hemida, M. G., Zowalaty, M. E. E., Abdel-Moneim, A. S., Ganesh, B., Tazerji, S. S., Natesan, S., Sircar, S., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.607886 · Cited by 23
Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals
Trinité, B., Pradenas, E., Marfil, S., Rovirosa, C., Urrea, V., Tarrés-Freixas, F., Ortiz, R., Rodon, J., Vergara‐Alert, J., Segalés, J., et al. (2021) · Viruses · doi:10.3390/v13061135 · Cited by 20
Molecular detection of SARS-CoV-2 being challenged by virus variation and asymptomatic infection
Jiang, C., Li, X., Ge, C., Ding, Y., Zhang, T., Cao, S., Meng, L., & Lu, S. (2021) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2021.03.006 · Cited by 21
A real-time and high-throughput neutralization test based on SARS-CoV-2 pseudovirus containing monomeric infrared fluorescent protein as reporter
Tsai, W.-Y., Ching, L. L., Hsieh, S., Melish, M. E., Nerurkar, V. R., & Wang, W. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1925163 · Cited by 22
COVID‐19: emergence and mutational diversification of SARS‐CoV‐2
Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13800 · Cited by 23
Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy
Damavandi, A. R., Dowran, R., Sharif, S. A., Kashanchi, F., & Jafari, R. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00729-6 · Cited by 21
Drug discovery and development targeting the life cycle of SARS-CoV-2
Su, H., Xu, Y., & Jiang, H. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.01.013 · Cited by 21
Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variant
Lee, C. Y., Amrun, S. N., Chee, R. S., Goh, Y. S., Mak, T. M., Octavia, S., Yeo, N. K., Chang, Z. W., Tay, M. Z., Torres‐Ruesta, A., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1241 · Cited by 20
HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development
Shepherd, B. L. O., Chang, D., Vasan, S., Ake, J. A., & Modjarrad, K. (2022) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00597-4 · Cited by 20
Coronavirus Genomes and Unique Mutations in Structural and Non-Structural Proteins in Pakistani SARS-CoV-2 Delta Variants during the Fourth Wave of the Pandemic
Anwar, M. Z., Lodhi, M. S., Khan, M. T., Khan, M. I., & Sharif, S. (2022) · Genes · doi:10.3390/genes13030552 · Cited by 21
The Comparison of Mutational Progression in SARS-CoV-2: A Short Updated Overview
Asif, A., Ilyas, I., Abdullah, M., Sarfraz, S., Mustafa, M., & Mahmood, A. (2022) · Journal of Molecular Pathology · doi:10.3390/jmp3040018 · Cited by 20
Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers
Kale, P. R., Gupta, E., Bihari, C., Patel, N., Rooge, S. B., Pandey, A. K., Bajpai, M., Khillan, V., Chattopadhyay, P., Devi, P., et al. (2021) · Vaccines · doi:10.3390/vaccines10010054 · Cited by 20
Structural determinants of spike infectivity in bat SARS-like coronaviruses RsSHC014 and WIV1
Qiao, S., & Wang, X. (2024) · Journal of Virology · doi:10.1128/jvi.00342-24 · Cited by 16
The pigtail macaque (Macaca nemestrina) model of COVID-19 reproduces diverse clinical outcomes and reveals new and complex signatures of disease
Melton, A., Doyle‐Meyers, L. A., Blair, R. V., Midkiff, C. C., Melton, H. J., Russell‐Lodrigue, K., Aye, P. P., Schiro, F. R., Fahlberg, M. D., Szeltner, D. M., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010162 · Cited by 19
Self-citation
Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore
Wang, B., Goh, Y. S., Prince, T., Ngoh, E. Z. X., Salleh, S. N. M., Hor, P. X., Loh, C. Y., Fong, S., Hartley, C. S., Tan, S. Y., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00389-2 · Cited by 19
Detection of live SARS-CoV-2 virus and its variants by specially designed SERS-active substrates and spectroscopic analyses
Sitjar, J., Liao, J., Lee, H., Tsai, H., Wang, J., Chen, C., Wang, H., & Liu, B. H. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.341151 · Cited by 18
SARS CoV-2 Nucleoprotein Enhances the Infectivity of Lentiviral Spike Particles
Mishra, T. K., Sreepadmanabh, M., Ramdas, P., Sahu, A. K., Kumar, A., & Chande, A. G. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.663688 · Cited by 18
Detection and Differentiation of SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses by CRISPR
Zhou, H., Tsou, J.-H., Chinthalapally, M., Liu, H., & Jiang, F. (2021) · Diagnostics · doi:10.3390/diagnostics11050823 · Cited by 16
Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens
Alameh, M., & Weissman, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821595-1.00014-2 · Cited by 17
Self-citation
Considering epitopes conservity in targeting SARS-CoV-2 mutations in variants: a novel immunoinformatics approach to vaccine design
Bagherzadeh, M. A., Izadi, M., Baesi, K., Jahromi, M. A. M., & Pirestani, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-18152-5 · Cited by 17
Establishment of a neutralization assay for Nipah virus using a high-titer pseudovirus system
Luo, X., Wang, C., Huang, Y., Cong, S., Tan, J., Hou, W., Ma, F., & Zheng, L. (2023) · Biotechnology Letters · doi:10.1007/s10529-023-03351-5 · Cited by 17
Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies
Beddingfield, B. J., Maness, N. J., Fears, A. C., Rappaport, J., Aye, P. P., Russell‐Lodrigue, K., Doyle‐Meyers, L. A., Blair, R. V., Carias, A. M., Madden, P. J., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.753444 · Cited by 15
Self-citation
European context of the diversity and phylogenetic position of SARS-CoV-2 sequences from Polish COVID-19 patients
Hryhorowicz, S., Ustaszewski, A., Kaczmarek-Ryś, M., Lis, E., Witt, M., Pławski, A., & Ziętkiewicz, E. (2021) · Journal of Applied Genetics · doi:10.1007/s13353-020-00603-2 · Cited by 15
Evolutionary Dynamics of Indels in SARS-CoV-2 Spike Glycoprotein
Rao, R. S. P., Ahsan, N., Xu, C., Su, L., Verburgt, J. C., Fornelli, L., Kihara, D., & Xu, D. H. (2021) · Evolutionary Bioinformatics · doi:10.1177/11769343211064616 · Cited by 14
Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies
Rice, A., Verma, M., Voigt, E. A., Battisti, P., Beaver, S., Reed, S., Dinkins, K., Mody, S., Zakin, L., Tanaka, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910136 · Cited by 15
Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination
Delshad, M., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109128 · Cited by 18
A potent, broadly protective vaccine against SARS-CoV-2 variants of concern
Wang, Z., An, J., Liu, K., Yü, P., Fang, X. D., Li, J., Zhu, H., Zhu, Q., Huang, C., Zhang, C., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00571-0 · Cited by 15
Spike D614G — A Candidate Vaccine Antigen Against Covid-19
Koenig, P.-A., & Schmidt, F. I. (2021) · New England Journal of Medicine · doi:10.1056/nejmcibr2106054 · Cited by 16
Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2
Xie, J., Ding, C., He, J., Zhang, Y., Ni, S., Zhang, X., Chen, Q., Wang, J., Huang, L., He, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.715464 · Cited by 16
SARS-CoV-2 Variants: Mutations and Effective Changes
Park, G., & Hwang, B. H. (2021) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-021-0327-3 · Cited by 17
Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine
Sun, Z., Jing, C., Zhan, H., Guo, X., Suo, N., Kong, F., Tao, W., Xiao, C., Hu, D., Wang, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1097472 · Cited by 16
Making sense of spike D614G in SARS-CoV-2 transmission
Shi, A. C., & Xie, X. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1893-9 · Cited by 15
Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primatesPreprint
Arunachalam, P. S., Walls, A. C., Golden, N., Atyeo, C. G., Fischinger, S., Li, C., Aye, P. P., Navarro, M. J., Lai, L., Edara, V. V., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.10.430696 · Cited by 15
Self-citation
Landscape-Based Protein Stability Analysis and Network Modeling of Multiple Conformational States of the SARS-CoV-2 Spike D614G Mutant: Conformational Plasticity and Frustration-Induced Allostery as Energetic Drivers of Highly Transmissible Spike Variants
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00124 · Cited by 16
Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation
Nguyen, H. V., Nguyen, H. L., Lan, P. D., Thai, N. Q., Sikora, M., & Li, M. S. (2023) · Chemical Society Reviews · doi:10.1039/d1cs01170g · Cited by 15
Are the emerging SARS-COV-2 mutations friend or foe?
Erol, A. (2021) · Immunology Letters · doi:10.1016/j.imlet.2020.12.014 · Cited by 14
Mutational Landscape and Interaction of SARS-CoV-2 with Host Cellular Components
Srivastava, M., Hall, D., Omoru, O. B., Gill, H. M., Smith, S., & Janga, S. C. (2021) · Microorganisms · doi:10.3390/microorganisms9091794 · Cited by 13
A comprehensive review of the analysis and integration of omics data for SARS-CoV-2 and COVID-19
Zhu, Z., Zhang, S., Wang, P., Chen, X., Bi, J., Cheng, L., & Zhang, X. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab446 · Cited by 14
A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
Brinkkemper, M., Brouwer, P. J. M., Maisonnasse, P., Grobben, M., Caniels, T. G., Poniman, M., Burger, J. A., Bontjer, I., Oomen, M., Bouhuijs, J. H., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00411-7 · Cited by 15
Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes
Qian, Z., Li, P., Tang, X., & Lü, J. (2022) · Medical Review · doi:10.1515/mr-2021-0035 · Cited by 14
Human interaction targets of SARS-CoV-2 spike protein: A systematic review
Faraji, S. N., Raee, M. J., Hashemi, S. M. A., Daryabor, G., Tabrizi, R., Dashti, F. S., Behboudi, E., Heidarnejad, K., Nowrouzi‐Sohrabi, P., & Hatam, G. (2022) · European Journal of Inflammation · doi:10.1177/1721727x221095382 · Cited by 16
The development and application of pseudoviruses: assessment of SARS-CoV-2 pseudoviruses
Tan, C., Wang, N., Deng, S., Wu, X., Yue, C., Jia, X., & Lyu, Y. (2023) · PeerJ · doi:10.7717/peerj.16234 · Cited by 14
Modulation of SARS-CoV-2 spike binding to ACE2 through conformational selection
Saha, P., Fernandez, I., Sumbul, F., Valotteau, C., Kostrz, D. N., Meola, A., Baquero, E., Sharma, A., Portman, J. R., Stransky, F., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01908-1 · Cited by 14
Network analysis uncovers the communication structure of SARS-CoV-2 spike protein identifying sites for immunogen design
Manrique, P. D., Chakraborty, S., Henderson, R. C., Edwards, R. J., Mansbach, R. A., Nguyen, K., Stalls, V., Saunders, C., Mansouri, K., Acharya, P., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105855 · Cited by 13
Self-citation
Delineating antibody escape from Omicron sublineagesPreprint
Gruell, H., Vanshylla, K., Korenkov, M., Tober‐Lau, P., Zehner, M., Münn, F., Janicki, H., Augustin, M., Schommers, P., Sander, L. E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.06.487257 · Cited by 13
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 11
Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach
Kwarteng, A., Asiedu, E., Sylverken, A. A., Larbi, A. A., Sakyi, S. A., & Asiedu, S. O. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104815 · Cited by 12
Computational analysis of protein stability and allosteric interaction networks in distinct conformational forms of the SARS-CoV-2 spike D614G mutant: reconciling functional mechanisms through allosteric model of spike regulation
Verkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1933594 · Cited by 12
COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era
Volkan, E. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00353-4 · Cited by 12
Immunity evasion: consequence of the N501Y mutation of the SARS-CoV-2 spike glycoprotein
Uzoeto, H. O., Ajima, J. N., Arazu, A. V., Ibiang, G. O., Cosmas, S., & Durojaye, O. A. (2022) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00287-z · Cited by 12
Protein expression/secretion boost by a novel unique 21-mer cis-regulatory motif (Exin21) via mRNA stabilization
Zhu, Y., Sarıbaş, A. S., Liu, J., Lin, Y., Bodnar, B. H., Zhao, R., Guo, Q., Ting, J., Wei, Z., Ellis, A., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.02.012 · Cited by 12
Cryo-electron microscopy in the study of virus entry and infection
Dutta, M., & Acharya, P. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1429180 · Cited by 12
Self-citation

Authors: Weissman, D., Alameh, M.-G., de Silva, T., Collini, P., Hornsby, H., Brown, R., LaBranche, C. C., Edwards, R. J., Sutherland, L., Santra, S., Mansouri, K., Gobeil, S., McDanal, C., Pardi, N., Hengartner, N., Lin, P. J. C., Tam, Y., Shaw, P. A., Lewis, M. G., Boesler, C., Şahin, U., Acharya, P., Haynes, B. F., Korber, B., & Montefiori, D. C.
Affiliations: University of Pennsylvania (US)
Sheffield Teaching Hospitals NHS Foundation Trust (GB)
University of Sheffield (GB)
Duke University (US)
Beth Israel Deaconess Medical Center (US)
Acuitas Therapeutics (Canada) (CA)
Bioqual (US)
BioNTech (Germany) (DE)
Los Alamos National Laboratory (US)
Corresponding author: Weissman, Drew
ORCID: Weissman, Drew
Alameh, Mohamad-Gabriel
Collini, Paul
Hornsby, Hailey
Brown, Rebecca
LaBranche, Celia C.
Edwards, Robert J.
Sutherland, Laura
Santra, Sampa
Mansouri, Katayoun
Gobeil, Sophie
McDanal, Charlene
Pardi, Norbert
Lin, Paulo J.C.
Tam, Ying
Shaw, Pamela A.
Lewis, Mark G.
Boesler, Carsten
Şahin, Uğur
Acharya, Priyamvada
Haynes, Barton F.
Korber, Bette
Montefiori, David C.
Venue: Cell Host & Microbe
Publisher: Elsevier BV
Published: 2021-01
Volume: 29
Issue: 1
Pages: 23-31.e4
ISSN: 1931-3128 (ISSN-L)
DOI: 10.1016/j.chom.2020.11.012
PMC: PMC7707640
OpenAlex: W3108737416
Cited by: 324
References: 57
Citations by year: 2026: 6 · 2025: 7 · 2024: 17 · 2023: 33 · 2022: 72 · 2021: 173
FWCI: 9.59
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 377 d)
Locations: Cell Host & Microbe (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
Funders: National Institutes of Health (75N93019C00050, HHSN272201800004C, R01 - AI145687)
Wellcome Trust (110058/Z/15/Z)
National Institute of Allergy and Infectious Diseases (AI142596, AI124429, R01AI123738, 1R01AI146101)
University of Pennsylvania
National Institute for Health Research
Laboratory Directed Research and Development (20200706ER)
Bill and Melinda Gates Foundation (OPP1146996)
UK Research and Innovation
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords: SARS-CoV-2, spike protein, D614G mutation, neutralizing antibodies, neutralization escape, receptor binding domain, monoclonal antibodies, convalescent sera, epitope exposure, vaccine efficacy, pseudovirus
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, COVID-19 Serotherapy, Adolescent, Adult, Animals, Antibodies, Monoclonal, Binding Sites, Female, Humans, Immunization, Passive, Macaca mulatta, Male, Mice, Inbred BALB C, Middle Aged, Mutation, Neutralization Tests, Mice, Young Adult, HEK293 Cells, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks